Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies

Fundamental and Clinical Pharmacology

Volumn 25, Issue 4, 2011, Pages 511-517

  Angel, Kristin ^a   Provan, Sella Aarrestad ^b   Hammer, Hilde Berner ^b   Mowinckel, Petter ^b   Kvien, Tore Kristian ^b,c   Atar, Dan ^a,c  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Arterial stiffness; Arthritis rheumatoid; Atherosclerosis; Inflammation; Vasculature

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANKYLOSING SPONDYLITIS; ARTERIAL STIFFNESS; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PULSE WAVE; RATING SCALE; RHEUMATOID ARTHRITIS; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; AORTA; ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BLOOD PRESSURE; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CAROTID ARTERIES; ELECTROCARDIOGRAPHY; FEMALE; FEMORAL ARTERY; HEALTH STATUS; HEART RATE; HUMANS; MALE; MANOMETRY; MIDDLE AGED; QUESTIONNAIRES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 79960003568     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00872.x     Document Type: Article

References (28)

1. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA (2006) 296 1735-1741.
2. Han C., Robinson D.W. Jr, Hackett M.V., Paramore L.C., Fraeman K.H., Bala M.V. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J. Rheumatol. (2006) 33 2167-2172.
3. Avina-Zubieta J.A., Choi H.K., Sadatsafavi M., Etminan M., Esdaile J.M., Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. (2008) 59 1690-1697.
4. Peters M.J., Symmons D.P., McCarey D. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. (2009) 69 325-331.
5. van Halm V.P., Peters M.J., Voskuyl A.E. et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann. Rheum. Dis. (2009) 68 1395-1400.
6. Dessein P.H., Stanwix A.E., Joffe B.I. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. (2002) 4 R5.
7. Panoulas V.F., Metsios G.S., Pace A.V. et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) (2008) 47 1286-1298.
8. del Rincon I.D., Williams K., Stern M.P., Freeman G.L., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. (2001) 44 2737-2745.
9. Choi H.K., Hernan M.A., Seeger J.D., Robins J.M., Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet (2002) 359 1173-1177.
10. Dixon W.G., Watson K.D., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. (2007) 56 2905-2912.
11. Jacobsson L.T., Turesson C., Gulfe A. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. (2005) 32 1213-1218.
12. Hurlimann D., Forster A., Noll G. et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation (2002) 106 2184-2187.
13. Maki-Petaja K.M., Hall F.C., Booth A.D. et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation (2006) 114 1185-1192.
14. van Eijk I.C., Peters M.J., Serne E.H. et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann. Rheum. Dis. (2009) 68 362-366.
15. Angel K., Provan S.A., Gulseth H.L., Mowinckel P., Kvien T.K., Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension (2010) 55 333-338.
16. Smolen J.S. Ten years of infliximab: insights from clinical trials in rheumatoid arthritis. Eur. J. Pharmacol. (2009) 623(Suppl) S5-S9.
17. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A., Garcia-Porrua C., Llorca J., Gonzalez-Gay M.A. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum. (2004) 51 447-450.
18. El Assaad M.A., Topouchian J.A., Asmar R.G. Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT. Blood Press. Monit. (2003) 8 127-133.
19. Wilkinson I.B., Fuchs S.A., Jansen I.M. et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J. Hypertens. (1998) 16 2079-2084.
20. Laurent S., Cockcroft J., Van B.L. et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur. Heart J. (2006) 27 2588-2605.
21. McEniery C.M., Wallace S., Mackenzie I.S. et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension (2006) 48 602-608.
22. Roman M.J., Devereux R.B., Schwartz J.E. et al. Arterial stiffness in chronic inflammatory diseases. Hypertension (2005) 46 194-199.
23. Stamatelopoulos K.S., Kitas G.D., Papamichael C.M. et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler. Thromb. Vasc. Biol. (2009) 29 1702-1708.
24. Wong M., Oakley S.P., Young L. et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2009) 68 1277-1284.
25. Vlachopoulos C., Dima I., Aznaouridis K. et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation (2005) 112 2193-2200.
26. Clapp B.R., Hingorani A.D., Kharbanda R.K. et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc. Res. (2004) 64 172-178.
27. Mathieu S., Joly H., Baron G. et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) (2008) 47 1203-1207.
28. Van D.S., McColl G., Wicks I.P. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) (2005) 44 1428-1432.